Analysts Have Conflicting Sentiments on These Healthcare Companies: Crispr Therapeutics AG (CRSP), Moderna (MRNA) and Disc Medicine (IRON)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Crispr Therapeutics AG (CRSP – Research Report), Moderna (MRNA – Research Report) and Disc Medicine (IRON – Research Report).
President's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Crispr Therapeutics AG (CRSP)
J.P. Morgan analyst Brian Cheng maintained a Buy rating on Crispr Therapeutics AG on February 13 and set a price target of $67.00. The company’s shares closed last Friday at $53.07.
According to TipRanks.com, Cheng is a 2-star analyst with an average return of
Currently, the analyst consensus on Crispr Therapeutics AG is a Moderate Buy with an average price target of $73.08, representing a 46.9% upside. In a report issued on January 30, Citizens JMP also maintained a Buy rating on the stock with a $80.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Moderna (MRNA)
Bernstein analyst Courtney Breen maintained a Hold rating on Moderna on February 13 and set a price target of $35.00. The company’s shares closed last Friday at $42.23, close to its 52-week low of $29.25.
According to TipRanks.com, Breen is a 5-star analyst with an average return of
The word on The Street in general, suggests a Hold analyst consensus rating for Moderna with a $32.25 average price target, which is a -22.9% downside from current levels. In a report issued on January 29, TD Cowen also maintained a Hold rating on the stock with a $40.00 price target.
Disc Medicine (IRON)
In a report issued on February 13, Stephen Willey from Stifel Nicolaus maintained a Buy rating on Disc Medicine. The company’s shares closed last Friday at $55.95.
According to TipRanks.com, Willey is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Disc Medicine with a $122.33 average price target, implying a 70.8% upside from current levels. In a report issued on February 3, Morgan Stanley also maintained a Buy rating on the stock with a $120.00 price target.
